EFSA health claim opinion

EFSA rejects Merck glucosamine-joint health claim

- Last updated on GMT

Related tags: Osteoarthritis

EFSA rejects Merck glucosamine-joint health claim
Glucosamine does not help maintain normal joint cartilage, the European Food Safety Authority (EFSA) has found after assessing a proprietary article 13.5 dossier submitted by drug giant, Merck Consumer Healthcare.

EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) found the claim to be unsubstantiated despite Merck referencing, “studies in patients with osteoarthritis, in healthy subjects, in animals and in vitro”. ​Twelve of those studies were human intervention studies and there were 13 reviews.

But the Panel said the human studies which it favours did not provide a strong case that glucosamine could help joints in healthy people.

“Weak”

“The evidence provided  by consensus opinions/reports from authoritative bodies  indicates that normal cells and tissues are  genetically (gene expression) and functionally different from osteoarthritic cells and tissues and therefore may respond differently to intervention with exogenous substances.”

“The Panel also notes that the evidence provided for  the proposed mechanisms which would explain an effect of glucosamine on joint cartilage is weak,” ​it said.

“The Panel concludes that a cause and effect relationship has not been established between the consumption of glucosamine and maintenance of normal joint cartilage in individuals without osteoarthritis (OA).”

“The Panel considers that results from studies in subjects with  OA relating to the treatment of symptoms of this disease (e.g. erosion of articular cartilage, and reduced function of joints) with glucosamine cannot be extrapolated to the target population.”

“Therefore, no scientific conclusions can be drawn from the studies on patients with OA for the substantiation of the claimed effect in subjects without OA.”

Glucosamine and chondroitin have both been rejected under the general function, article 13 claims register, and the opinions have already been cited by local agencies such as the advertising watchdog in the UK - the Advertising Standards Authority (ASA).

The NDA opinion can be found here.

Related news

Show more

Related products

show more

Proven Efficacy of Delphinol® on Bone Health

Proven Efficacy of Delphinol® on Bone Health

Anklam Extrakt GmbH | 21-Oct-2019 | Research Study

Within the course of a preclinical study covering in vitro and in vivo analyses, the effect of a polyphenol-rich maqui berry extract (Delphinol®) on bone...

MenaQ7® Partners Benefit From K2 Outreach

MenaQ7® Partners Benefit From K2 Outreach

NattoPharma USA, Inc. | 22-Apr-2019 | Case Study

MenaQ7® K2 as MK-7 provides health benefits for all ages. That is a fact clinically proven by NattoPharma and communicated to practitioners and consumers...

GlycOmega™-PLUS: Beyond Greenshell™ mussel powder

GlycOmega™-PLUS: Beyond Greenshell™ mussel powder

LEHVOSS Nutrition | 04-Feb-2019 | Technical / White Paper

From Aroma NZ Ltd, GlycOmega™ PLUS is the new generation of Greenshell™ mussel meat extract, which LEHVOSS Nutrition is pleased to add to the Gee Lawson...

Related suppliers

Follow us

Products

View more

Webinars